Company profile: MirImmune Bio
1.1 - Company Overview
Company description
- Provider of biopharmaceutical R&D focused on new and improved cancer immunotherapies, combining immune checkpoint inhibition and cell-based immunotherapies, aiming to achieve long-term survival of cancer patients.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MirImmune Bio
Epsilogen
HQ: United Kingdom
Website
- Description: Provider of immuno-oncology therapies developing immunoglobulin antibodies for cancer, focusing on IgE-based drugs for solid tumors. Offerings include MOv18 IgE, targeting folate receptor alpha for ovarian cancer with Phase I safety and early clinical activity, and an IgEG fusion platform combining IgE and IgG to enhance potency and serum half-life, with in vitro and in vivo proof of concept.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epsilogen company profile →
ProstaGene
HQ: United States
Website
- Description: Provider of biotechnology solutions integrating proprietary molecular diagnostics with novel therapeutic screening and commercial experience to develop novel cancer treatments, based on the patents of founder Dr. Richard G. Pestell; early-stage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProstaGene company profile →
Actuate Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics and clinical research focused on elraglusib for high-impact cancers and neurodegenerative diseases, including adult and pediatric injection and oral tablet formulations for advanced, refractory solid and hematological cancers (e.g., pancreatic, metastatic melanoma, colorectal), combination regimens with chemotherapy, ongoing trials to assess efficacy and safety, and partnerships with academic and scientific organizations
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Actuate Therapeutics company profile →
Tharimmune
HQ: United Kingdom
Website
- Description: Provider of development-stage therapeutics for cancer and chronic pruritus, including TH104, a transmucosal buccal film with nalmefene targeting µ- and kappa-opioid receptors and inhibiting IL-17 for pruritus in PBC and other conditions; TH3215, a bispecific HER2/HER3 antibody; and TH1940, an anti-PD-1 Picobody therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tharimmune company profile →
BioMark Diagnostics
HQ: Canada
Website
- Description: Provider of oncology-focused metabolomics-based cancer detection solutions, including a liquid biopsy metabolic panel for early lung cancer diagnosis using urine and plasma, a non-invasive SSAT1 assay leveraging an FDA-approved drug to detect elevated enzyme levels in cancers, a metabolomics-driven detection platform, lung cancer early detection studies, and cancer education videos.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioMark Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MirImmune Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MirImmune Bio
2.2 - Growth funds investing in similar companies to MirImmune Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MirImmune Bio
4.2 - Public trading comparable groups for MirImmune Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →